Cited 87 times in
Weekly rituximab followed by monthly rituximab treatment for steroid-refractory chronic graft-versus-host disease: results from a prospective, multicenter, phase II study.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.